Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases.
Fiche publication
Date publication
janvier 2020
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Lagrange J, Lacolley P, Wahl D, Peyrin-Biroulet L, Regnault V
Lien Pubmed
Résumé
Patients with inflammatory bowel diseases (IBD) have an increased risk of thrombosis, possibly due to changes in blood cells and molecules involved in hemostasis. They have increased platelet counts and reactivity as well as increased platelet-derived large extracellular vesicles. Coagulation is continuously activated in patients with IBD, based on measured markers of thrombin generation, and the anticoagulant functions of endothelial cells are damaged. Furthermore, fibrinogen is increased and fibrin clots are denser. However, pathogenesis of thrombosis in patients with IBD appears to differ from that of patients without IBD. Patients with IBD also take drugs that might contribute to risk of thrombosis, complicating the picture. We review the features of homeostasis that are altered in patients with IBD and possible mechanisms of this relationship.
Mots clés
fibrinolysis, inflammatory bowel disease, platelet, thrombosis
Référence
Clin. Gastroenterol. Hepatol.. 2020 Jan 20;: